Induction Chemo-Nivo in Unresectable Stage III NSCLC

Exclusion Criteria

• •Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment
• •Any prior radiotherapy to the lung
• •Any prior treatment for NSCLC
• •Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
• •Any history of a severe hypersensitivity reaction to any monoclonal antibody
• •Any history of allergy to the study drug components
• •primary tumors involving the esophagus
• •pancoast tumors
• •Patients cannot have primary tumors which would remain unresectable
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab or other agents used in study
• •Any active or history of autoimmune disease (including any history of inflammatory bowel disease), or history of syndrome that required systemic steroids or immunosuppressive medications
• •Ongoing requirement for systemic corticosteroids greater than the equivalent of prednisone 10mg
• •previous malignancies
• •history of interstitial lung disease
• •Patients requiring continuous supplemental oxygen
• •Use of any live vaccines against infectious diseases (e.g., influenza, varicella. etc.) within 4 weeks (28 days) of initiation of study therapy
• •Active systemic infection requiring therapy
• •Patients with uncontrolled intercurrent illness
• •Patients with psychiatric illness/social situations that would limit compliance with study requirements
• •Pregnant or lactating women